ProFibrix Secures Funding for Progression of Lead Product Into Late Stage Clinical Development and Announces Management and Supervisory Board Appointments

LEIDEN, The Netherlands and SEATTLE, May 3, 2011 - ProFibrix B.V., a leader in the development of innovative
products that help stop bleeding (hemostasis) after surgery, today announced
the successful closing of a series B follow-on financing. In conjunction with
the financing and to support the company's next stage of development towards
commercialization, ProFibrix also announced several management and
Supervisory Board appointments.

The Supervisory Board will be chaired by independent director
Leonard Kruimer, Chief Financial Officer of Crucell. Over the past decade,
Mr. Kruimer has been instrumental in building Crucell from an entrepreneurial
start-up into a global vaccine company, taking the company public and leading
a number of large and successful M&A transactions. Also joining the
Supervisory Board as an independent director is Vic Schmitt. Mr. Schmitt has
been a long-time senior executive at Baxter International, a key player in
the hemostasis market, where he last served as President of Venture
Management.

In addition to these high profile appointments to the
Supervisory Board, Jan Ohrstrom, has been named Chief Executive Officer.
Before joining ProFibrix, Dr. Ohrstrom was a senior executive at
ZymoGenetics, where he was responsible for the development of several
products, and a member of the team that took the company public. Dr. Ohrstrom
started his career at Novo Nordisk. Jaap Koopman, founding CEO of ProFibrix,
will become Chief Scientific Officer.

In addition to the private funding the company was awarded a
government credit, bringing the total new funds available to the company for
the progression of Fibrocaps(TM) to EUR 15 million (USD 22 million). New
investors Vesalius Biocapital and INKEF Capital co-led the financing round,
while existing investors Index Ventures and Gilde Healthcare Partners also
participated. Alain Parthoens from Vesalius Biocapital, Dirk Kersten from
Gilde Healthcare Partners, and Francesco De Rubertis from Index Ventures will
also hold seats on the board of ProFibrix.

The proceeds of the financing will be used to progress the
company's lead product Fibrocaps into late stage clinical development, as
well as to support the company's other pipeline programs. Fibrocaps is
currently being investigated in a prospective, multi-center Phase II study in
multiple surgical indications at up to 20 sites, including major U.S. and
Dutch academic medical centers. If this study confirms the positive results
of the first Phase II trial, ProFibrix anticipates initiating a pivotal Phase
III trial in early 2012, and file for approval by the U.S. Food and Drug
Administration in early 2013.

Jan Ohrstrom, MD, said: "We are very pleased to welcome
Vesalius Biocapital and INKEF Capital to our investor base. Our successful
financing and strengthened Supervisory Board and leadership team should put
ProFibrix in an excellent position to continue the development of Fibrocaps
and prepare for its commercial launch. We would like to extend our gratitude
to the parting board members for their contribution and commitment to the
early development of ProFibrix."

Jaap Koopman said: "Jan Ohrstrom has played a key role in
transitioning ProFibrix to a market-focused company. He has the capabilities
and skills to take ProFibrix through its next stages of growth to become a
leading hemostasis company. I look forward to seconding him in his new role
as CEO, and to continue to contribute to the development of new products
based on our fibrinogen technology platform."

About Fibrocaps

Fibrocaps is based on a mixture of two essential blood
clotting proteins, fibrinogen and thrombin, and is a unique dry powder
topical tissue sealant that rapidly stops bleeding after or during surgery.
Fibrocaps has major advantages over existing liquid tissue sealants: it is
ready for immediate use, is stable at room temperature, highly effective and
fast acting.

About ProFibrix

ProFibrix (www.ProFibrix.com) was founded in 2004 and
is headquartered in Leiden, The Netherlands, with a subsidiary in Seattle,
WA, USA. The company leverages its expertise in fibrinogen technology to
develop and market innovative products for the hemostasis and regenerative
medicine markets. Human fibrinogen plays a pivotal role in blood clotting and
tissue healing. ProFibrix is led by a team with extensive commercial,
clinical and scientific experience in the hemostasis field.

About Vesalius Biocapital

Vesalius focuses on the creation, financing and growth of
early-stage life science companies. The managed Vesalius funds invest in
areas with a high unmet medical need and a significant profit potential: new
therapeutics, cutting-edge medical devices, innovative drug delivery
technologies and diagnostic tests and instruments with a high utility level.
The expertise of the team ranges from extensive investment and exit
experience to corporate governance, operational experience, business
development, research & development, and IP management in start-ups and
mature life science companies. Furthermore, individual team members have
in-depth technical insights and competitive scouting experience in the life
science sector. For more information, please visit
www.vesaliusbiocapital.com.

About INKEF Capital

INKEF Capital, founded in 2010 to create a new way of
investing in start-ups, is an international alliance of two major pension
funds, ABP from the Netherlands, and Canadian pension plan OMERS. INKEF
Capital is investing in the knowledge economy of the future. The fund will
invest from an early stage, and can continue to provide financing to
successful investee companies all the way to a sale or an IPO. The fund's
long term investment strategy is to achieve top quartile returns consistent
with the risk profile of the investment class. For more information, please
visit www.inkefcapital.com

About Index Ventures

Index Ventures is a leading pan-European venture capital firm
dedicated to working with entrepreneurs who have the drive and ability to
build world-class technology and life science companies. The Index Ventures
team, which began investing in 1992, has a deep technology and scientific
focus and the ability to leverage a network of cross-Atlantic strategic
relationships. Index proactively seeks out the top entrepreneurial teams in
each investment area and leverages its core assets in helping the
entrepreneurs build their companies into global leaders. Index Ventures
investors include leading technology firms and institutional investors.
Previous investments include Pangenetics, Genmab, Aegerion, SGX
Pharmaceuticals, Inc., ParAllele Bioscience and Molecular Partners. For more
information, please visit www.indexventures.com.

About Gilde Healthcare Partners

Netherlands-based Gilde Healthcare Partners is a transatlantic
venture and growth capital firm focused on private healthcare technologies
and services. It has over EUR400 million under management and is actively
looking to lead new investments in therapeutics, diagnostics, medical devices
and services. Gilde successfully builds healthcare businesses across Europe
and US, investing up to EUR15 million in a single portfolio company. By
investing in companies with clear, achievable business models, Gilde has used
its financial resources and network to create significant value for both its
investors and the entrepreneurs it backs. For a list of Gilde's portfolio
companies please visit the website at www.gildehealthcare.nl.

For further enquiries: Jan Ohrstrom, MD, CEO, ProFibrix, +1-206-9105-404, +31-63-1774-620, j.ohrstrom at profibrix.com. Hans Herklots, Principal, Capricorn One, +41-79-598-7149, capricorn1 at bluewin.ch